Boston Scientific Corp (BSX) has had a mixture of fluctuating stock prices and considerable movements in acquiring and expanding its portfolio in the biotech industry. Furthermore, several Wall Street analysts issued a 'Moderate Buy' on BSX stock based on the company's recent Q3 earnings results exceeding market expectations. The company is persistently fortifying its presence with consistent revenue and EPS beats, growth in heart devices demand, and
increased 2024 guidance. It finalized acquisition of
Axonics, Inc,
Intera Oncology® Inc,
Silk Road Medical, Inc., and
Cortex, Inc., expanding its coverage in oncology and urology sectors. The company's
share prices were raised twice to an expected target of $110. It also remained a compelling investment in Billionaire Ken Griffin's portfolio. However, BSX has experienced
trade-offs in the stock market, underperforming on some days compared to its competitors. It received Japanese regulatory approval for its
FARAPULSE™ Pulsed Field Ablation System and successfully launched the same in other countries. Besides, the FDA issued a notification that Boston Scientific pacemakers might need early replacement.
Boston Scientific Corp BSX News Analytics from Wed, 31 Jan 2024 08:00:00 GMT to Fri, 20 Dec 2024 17:56:06 GMT -
Rating 5
- Innovation 8
- Information 8
- Rumor -8
